# A211 INCREASED RATES OF PPI DEPRESCRIPTION OVER TIME IN PATIENTS WITH UPPER GI BLEEDS

**Authors:** K Kecskemeti, M Borgaonkar, J Mcgrath

PMC · DOI: 10.1093/jcag/gwad061.211 · Journal of the Canadian Association of Gastroenterology · 2024-02-14

## TL;DR

This study found that more patients stopped or reduced proton pump inhibitors after upper GI bleeds in recent years compared to earlier periods.

## Contribution

The study demonstrates a significant increase in PPI deprescription rates over time in patients with upper GI bleeds.

## Key findings

- PPI deprescription rates increased from 2% in 2015-2018 to 16% in 2019-2022.
- The difference in deprescription rates between the two time periods was statistically significant (p < 0.001).

## Abstract

Proton Pump Inhibitors (PPIs) are commonly used for various indications, including prophylaxis of upper GI bleeding. We aimed to assess if there has been more PPI deprescription in recent years in patients treated for Upper GI Bleeds (UGIB).

Our study aimed to assess the frequency of PPI deprescription in patients treated with endoscopic therapy for UGIBs. We hypothesized that there was a higher rate of PPI deprescription in recent years.

This retrospective cohort study analyzed patients who received endoscopic treatment for UGIB between the years 2015-2022. All patients who were treated with endoscopic therapy for an UGIB from two academic GI practices were included. PPI deprescription was defined as a 50% dose reduction, frequency reduction or complete medication discontinuation in the past 3 months or longer in established PPI users. To assess trends, the cohort was divided into group 1 (2015-2018) and group 2 (2019-2022). Data were analysed using SPSS and chi-squared testing was used to compare categorical variables.

Data were collected from 301 UGIB treated endoscopically. The mean age was 66.4 ± 13.5 years with 64% males and 36% females. Patients from group 1 had a deprescription rate of 2% (2/101 cases). Patients from group 2 (2019-2022) had a deprescription rate of 16% (32/200 cases) (pampersand:003C0.001).

There was a higher rate of PPI deprescription in patients treated for UGIB in the second time period. Reasons for the increased rate of PPI deprescription require further investigation.

Chi-Squared of PPI Deprescription for entire cohort

Fisher Exact test: P value ampersand:003C0.001

None

---
Source: https://tomesphere.com/paper/PMC10872112